Skip to main content
. 2021 Mar 13;11(11):5491–5510. doi: 10.7150/thno.55041

Figure 7.

Figure 7

AntagomiR-143/145 prevents and agomiR-143/145 exacerbates OVX-induced bone loss. (A) Representative micro-CT images of trabecular and cortical bone from control, antagomiR-NC, and antagomiR-143/145 treated femurs. (B) Quantitative measurements of Tb. BV/TV, Tb. BMD and Ct. Th. (C) Dynamic histomorphometry analysis of Tb and Eb bone including the quantification (D) of MAR and BFR/BS. Scale bars: 20 μm. (E) HE staining showing an overall trabecular bone mass. Scale bars: 200 μm. (F) Quantification of osteoblast numbers and surface on the trabecular. (G) Quantification of osteoclast numbers and surface on the trabecular. (H) Micro-CT images of trabecular from control, agomiR-NC, and agomiR-143/145 treated mice. (I) Measurements of Tb. BV/TV, Tb. BMD and Ct. Th in respective femurs. (J) Quantification of MAR and BFR/BS in Tb and Eb bone. (K) Representative images of HE staining showing an overall trabecular bone mass. Scale bars: 200 μm. (L) Quantification of osteoblast numbers and surface on the trabecular. (M) Quantification of osteoclast numbers and surface on the trabecular. Results are presented as the mean ± S.D. *p < 0.05; #p > 0.05 by one-way ANOVA, n = 6 mice per group.